Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2007-07-31
2007-07-31
Levy, Neil S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S451000, C424S465000, C424S466000, C424S468000, C424S471000, C424S472000, C514S197000, C514S210060
Reexamination Certificate
active
09689483
ABSTRACT:
Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
REFERENCES:
patent: 4282202 (1981-08-01), Dowrick
patent: 4301149 (1981-11-01), Crowley
patent: 4303582 (1981-12-01), Shean et al.
patent: 4427690 (1984-01-01), Cole et al.
patent: 4441609 (1984-04-01), Crowley
patent: 4525352 (1985-06-01), Cole et al.
patent: 4537887 (1985-08-01), Rooke et al.
patent: 4673637 (1987-06-01), Hyman
patent: 4950484 (1990-08-01), Olthoff et al.
patent: 5051262 (1991-09-01), Panoz et al.
patent: 5077790 (1991-12-01), Shell
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5158779 (1992-10-01), Gergely et al.
patent: 5225197 (1993-07-01), Bolt et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5487901 (1996-01-01), Conte et al.
patent: 5500227 (1996-03-01), Oshlack et al.
patent: 5582837 (1996-12-01), Shell
patent: 5650169 (1997-07-01), Conte et al.
patent: 5670170 (1997-09-01), Grimmett et al.
patent: 5681583 (1997-10-01), Conte et al.
patent: 5690959 (1997-11-01), Palepu et al.
patent: 5733577 (1998-03-01), Myers et al.
patent: 5738874 (1998-04-01), Conte et al.
patent: 5741524 (1998-04-01), Staniforth et al.
patent: 5814337 (1998-09-01), Merrifield et al.
patent: 5849330 (1998-12-01), Marvola et al.
patent: 5851550 (1998-12-01), Martin et al.
patent: 5858412 (1999-01-01), Staniforth et al.
patent: 5861172 (1999-01-01), Martin et al.
patent: 5910322 (1999-06-01), Rivett et al.
patent: 5962022 (1999-10-01), Bolt et al.
patent: 5972389 (1999-10-01), Shell et al.
patent: 6027748 (2000-02-01), Conte et al.
patent: 6051254 (2000-04-01), Merrifield et al.
patent: 6051255 (2000-04-01), Conley et al.
patent: 6077536 (2000-06-01), Merrifield et al.
patent: 6090411 (2000-07-01), Pillay et al.
patent: 6110497 (2000-08-01), Martin et al.
patent: 6126969 (2000-10-01), Shah et al.
patent: 6136345 (2000-10-01), Grimmett et al.
patent: 6177421 (2001-01-01), Moir et al.
patent: 6183778 (2001-02-01), Conte et al.
patent: 6183780 (2001-02-01), Van Balken et al.
patent: 6214359 (2001-04-01), Bax
patent: 6294199 (2001-09-01), Conley et al.
patent: 6294200 (2001-09-01), Conte et al.
patent: 6299903 (2001-10-01), Rivett et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 6352720 (2002-03-01), Martin et al.
patent: 6358528 (2002-03-01), Grimmett et al.
patent: 6372255 (2002-04-01), Saslawski et al.
patent: 6399086 (2002-06-01), Katzhendler et al.
patent: 6783773 (2004-08-01), Storm et al.
patent: 6878386 (2005-04-01), Conley et al.
patent: 2001/0018070 (2001-08-01), Shell et al.
patent: 2001/0026809 (2001-10-01), Oshlack et al.
patent: 2001/0038838 (2001-11-01), Burch
patent: 2001/0043926 (2001-11-01), Burch
patent: 2001/0046984 (2001-11-01), Rudnic
patent: 2001/0048944 (2001-12-01), Rudnic et al.
patent: 2002/0001616 (2002-01-01), Conley
patent: 2002/0004071 (2002-01-01), Cherukuri
patent: 2002/0004499 (2002-01-01), Rudnic et al.
patent: 2002/0006433 (2002-01-01), Davidson et al.
patent: 2002/0064562 (2002-05-01), Martin et al.
patent: 2002/0086056 (2002-07-01), Grimmett et al.
patent: 2002/0099044 (2002-07-01), Bax et al.
patent: 0080862 (1982-11-01), None
patent: 0131147 (1985-01-01), None
patent: 0080862 (1985-09-01), None
patent: 0080862 (1985-09-01), None
patent: 0222914 (1987-05-01), None
patent: 0234670 (1987-09-01), None
patent: 0281200 (1988-02-01), None
patent: 0389177 (1990-03-01), None
patent: 0396335 (1990-11-01), None
patent: 0131147 (1996-12-01), None
patent: 0131147 (1996-12-01), None
patent: 1004680 (2000-10-01), None
patent: 1508977 (1978-04-01), None
patent: 2005538 (1979-04-01), None
patent: WO 91/15197 (1991-10-01), None
patent: WO 92/19227 (1992-11-01), None
patent: WO 93/00898 (1993-01-01), None
patent: WO 94/06416 (1994-03-01), None
patent: WO 94/16696 (1994-08-01), None
patent: WO 94/27557 (1994-12-01), None
patent: WO 94/27600 (1994-12-01), None
patent: WO 95/20946 (1995-08-01), None
patent: WO 95/25516 (1995-09-01), None
patent: WO 95/28148 (1995-10-01), None
patent: WO 95/28927 (1995-11-01), None
patent: WO 95/33487 (1995-12-01), None
patent: WO 96/04907 (1996-02-01), None
patent: WO 96/04908 (1996-02-01), None
patent: WO 96/07408 (1996-03-01), None
patent: WO 96/34605 (1996-11-01), None
patent: WO 97/09042 (1997-03-01), None
patent: WO 98/05305 (1998-02-01), None
patent: WO 98/07424 (1998-02-01), None
patent: WO 98/22091 (1998-05-01), None
patent: WO 98/35672 (1998-08-01), None
patent: WO 98/40054 (1998-09-01), None
patent: WO 98/42311 (1998-10-01), None
patent: WO 99/25343 (1999-05-01), None
patent: WO 99/47125 (1999-09-01), None
patent: WO 99/62910 (1999-12-01), None
patent: WO 00/03695 (2000-01-01), None
patent: WO 00/12088 (2000-03-01), None
patent: WO 00/23045 (2000-04-01), None
patent: WO 00/41478 (2000-07-01), None
patent: WO 00/44353 (2000-08-01), None
patent: WO 00/61116 (2000-10-01), None
patent: W0 01/00177 (2001-01-01), None
patent: WO 01/13883 (2001-03-01), None
patent: WO 01/56544 (2001-08-01), None
patent: WO 01/62231 (2001-08-01), None
patent: WO 01/80824 (2001-11-01), None
patent: WO 02/30392 (2002-04-01), None
patent: WO 01/49618 (2002-06-01), None
patent: WO 03/17985 (2003-03-01), None
The Merck Index, Eleventh Edition, 1989, p. 2342.
PDR, Augmentin, pp. 2637-2641, 1997.
Amendola et al., “Pediatric suspension of amoxycillin and clavulanic acid in the treatment of bacterial infections of the upper respiratory tract and ear”, Minerva Pediatrica, 1989, vol. 41, No. 2, pp. 97-103.
Arguedas et al., “In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid”, J. Antimicrob. Chemother., 1991, 27(3), pp. 311-318.
Astruc, “Efficacy and tolerance of a new formulation amoxicillin 100 mg—clavulanic acid 12.5 mg in acute otitis media in infants”, Annales De Pediatrie, 1992, vol. 39, No. 2, 142-148.
Aulton et al., “The Mechanical Properties of Hydroxypropylmethylcellulose Films Derived from Aqueous Systems”, Drug Development and Industrial Pharmacy, 1981, 7(6), pp. 649-668.
Ball et al., “Clavulanic Acid and Amoxycillin: A Clinical, Bacteriological, and Pharmacological Study”, The Lancet, Mar. 22, 1980, vol. 1, pp. 620-623.
Baron et al., “Antimicrobial therapy in acute otitis media”, Traitement Antibiotique de L'Otite Moyenne Aigue, Annales de Pediatrie, 1991, 38(8), pp. 549-555.
Barry et al., “Effect of Increased Dosages of Amoxycillin in Treatment of Experimental Middle Ear Otitis Due to Penicillin-ResistantStreptococcus pneumoniae”, Antibacterial Agents and Chemotherapy, Aug. 1993, vol. 37, No. 8, pp. 1599-1603.
Beghi et al., “Efficacy and Tolerability of Azithromycin versus Amoxicillin/Clavulanic Acid in Acute Purulent Exacerbation of Chronic Bronchitis”, Journal of Chemotherapy, 1995, 7(2), pp. 146-152.
Berry et al., “Comparative Efficacy of Gemifloxacin in Experimental Models of Pyelonephritis and Wound Infection”, Journal of Antimicrobial Chemotherapy, 2000, No. 45, supplement S1 pp. 79-85.
Bottenfield et al., Safety and Tolerability of a New Formulation . . . In the Empiric Treatment of Pediatric . . .Streptococcus pneumoniae,Pediatrict Infect. Dis. J., vol. 17, pp. 963-968 (1998).
Brooks et al., “Pleuromutilins, Part 1: The Identification of Novel Mutilin 14-Carbamates”, Bioorganic and Medicinal Chemistry 9, 2001, pp. 1221-1231.
Calver et al., “Amoxicillin/Clavulanate BID vs A/C TID in the Treatment of Lower Respiratory Tract Infections”, Abstracts of the 35th ICAAC, 1995, p. 334.
Calver et al., “Augmentin Bid Versus Augmentin TID in the Treatment of Lower Respiratory Tract Infections”, Can. J. Infect Dis., 1995, vol. 6 Suppl C, Abstract No. 0338, p. 239C ABSTRACT.
Calver et al., “Dosing of Amoxicillin/Clavulanate Given Every 12 Hours is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection”, Clinical Infectious Disease, 199
Conley Creighton P.
Roush John A.
Storm Kevin H.
Beecham Pharmaceuticals (Pte) Limited
Dinner Dara L.
Kinzig Charles M.
Levy Neil S.
Venetianer Stephen
LandOfFree
Method of treating a bacterial infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating a bacterial infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating a bacterial infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3767508